Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

Details for Australian Patent Application No. 2005215254 (hide)

Owner Engeneic Molecular Delivery Pty Ltd.

Inventors Brahmbhatt, Himanshu; MacDiarmid, Jennifer

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2005215254

PCT Pub. Number WO2005/079854

Priority 60/540,590 02.02.04 US

Filing date 27 January 2005

Wipo publication date 1 September 2005

Acceptance publication date 12 November 2009

International Classifications

A61K 47/00 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

A61K 9/50 (2006.01) Medicinal preparations characterised by special physical form - Microcapsules

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

14 September 2006 PCT application entered the National Phase

  PCT publication WO2005/079854 Priority application(s): WO2005/079854

12 November 2009 Application Accepted

  Published as AU-B-2005215254

11 March 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005215257-Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists

2005215250-N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof